• Rocío Arroyo, President, AseBio – Spanish Bioindustry Association
• Eider Mendoza Larrañaga, Deputy General, Gipuzkoa Provincial Council
• Eneko Goia Laso, Mayor of Donostia/San Sebastián

A review of the investment activity recorded for the year 2023 in the biotech industry. 2022 marked a return to normal growth rates after two spectacular years in the context of the COVID-19 pandemic. In this session we will review if an adverse macroeconomic scenario had an impact on private investment activity on 2023 and what are the prospects for the short-mid-term in Spain.

Sponsored by:

• Ion Arocena, CEO, AseBio – Spanish Bioindustry Association
• Alberto Sanz, Finance and Investor Relations Director, Invest in Spain

• Doctomatic, Carmen Pauline Rios Benton, CEO
• Adamo Robot, Francesco Di Martino, VP of Sales
• ADNTRO Genetics, Guillermo Pérez-Solero, CEO
• Oniria Therapeutics, Esther Rimbau, CEO
• Aquilon Cyl, Luis Ruiz, Executive President
• DIVE Medical, Marta Ortín,  CTO – Cofounder
• Flomics Biotech, João Curado,  CEO
• Gate2Brain, Meritxell Teixido, CEO
• Inhibitec Anticuerpos, Gabriel Mesquida, CEO
• Innoup Farma, Maite Agüeros,  CEO
• Integra Therapeutics, Avencia Sanchéz-Mejías,  CEO
• Batea Oncology, Sonia Martínez Arca,  CEO
• Mikrobiomik Healthcare, Patricia Del Río,  Business Development & Innovation Director
• Miramoon Pharma, Virginia Arechavala Gomeza, CEO y Co-founder
• Nanodecal, Roberto de la Rica, CEO
• Genbioma Aplicaciones, Josune Ayo,  Co-founder&CEO
• Nucaps, Mariano Oto. CEO
• Onena Medicines. Neethan Lobo.  CEO
• Allinky Biopharma, Asunción Burguete, Head of Business Development
• Peaches Biotech, Juan Carlos de Gregorio,  CEO
• ZeCardio Therapeutics, Davide D’Amico, CEO

Secondary markets are an obvious exit strategy for venture capital funds from their biotech holdings in their portfolio. However, in Europe and Spain in particular, this option is still limited to a handful of companies, a far cry from what we see in the US. In this session, Euronext’s head of listing, a VC fund partner and a company quoted in the stock market will examine some of the issue. Barriers to listing and maturity of the ecosystem will be examined. The new European Listing Act and its pending transposition to national law will be analyzed. Finally, we will consider how the current macroeconomic environment is hampering or facilitating new IPOs.

Sponsored by:

• Julia Salaverría, Managing Partner, Ysios Capital

• Susana de Antonio, Head of Listing, Euronext
• Clara Campás, Managing Partner, Asabys Partners
• José María Huch, CFO, Atrys Health
• Clément Bertholet, General Partner, AdBio Partners

Creative and alternative funding mechanisms will be explored. This session will discuss alternative secondary markets such as BME Scale up, a stock market aimed primarily at companies in an early stage of development with a proven and scalable business model for any sector. In addition, some experiences with creative instruments such as reverse mergers will be discussed.

Sponsored by:

• Emma Gasol, Investment Director, AdBio Partners

• Jesús González Nieto-Márquez, Managing Director, BME Growth & BME Scaleup
• Antonio Herce, Investment Director, Inveready
• Carlos Buesa, CEO, Oryzon Genomics

The GANTT (Gipuzkoa Advanced New Therapies Territory) strategy of the Provincial Council of Gipuzkoa aims to accelerate and create an ecosystem that facilitates the generation of the value chain (manufacturing ecosystem) in the field of advanced therapies. This session explains how we are seeking to turn Gipuzkoa into a privileged destination in the field of investment in Biosciences.

Sponsored by:

• Ainhoa Aizpuru, Project Manager, BIC Gipuzkoa Berrilan

• Ane Insausti, Deputy for Economic Promotion and Strategic Projects, Provincial Council of Gipuzkoa
• Héctor Olabegogeaskoetxea, Managing Director, Mondragon Health
• Javier García Cogorro, General Partner, Columbus Venture Partners
• Jimmy Vanhove, CEO, Viralgen
• Guillermo Arregui, Founder & CEO, Double Helix

This round table will explore how public-private collaboration is enabling the development of powerful funding instruments. A representative of the European Investment Bank will delve into the EIC programme and how it ties in with their co-investment programmes to foster venture capital firm activity. Admit CEO, Marta Barrachina will share how their inspiring story of success was ignited by funding through the EIC programme. Ysios, a leading European biotech firm, will explain how these instruments are implemented from the perspective of corporate equity funds/VC fund.

Sponsored by:

• Sixto de la Calle, Partner, Head of Private Equity and Venture Capital, Eversheds-Sutherland

• Myriam Rouis, Senior Investment Manager / Advisor – EIC Fund, European Investment Bank
• Guillem Laporta, Partner, Ysios Capital
• Marta Barrachina, CEO and Co-Founder, ADmit Therapeutics
• Carles Domènech, CEO, Ability Pharmaceuticals

With this session we want to deep in the potential of the bioeconomy. How investments are being directed towards projects that contribute to environmental sustainability and a more sustainable diet in Spain.

Sponsored by:

• Ion Arocena, CEO, AseBio & Partner of the European Commission’s ShapingBio project

• Rubén Hidalgo,  Director of Innovation and Entrepreneurship Ecosystems, CAPSA (Peñasanta Food Corporation S.A.)
• Nora Alonso, Partner and Chief Investment Officer of the Agri-Food Tech Fund, Swanlaab Venture Factory
• Eduardo Pérez, Analyst, Tech Transfer Agrifood Fund,  Clave Capital

Speakers will debate about alternative funding instruments that are accelerating development of biotech startups and SMEs. Day One’s early-stage funding, financial solutions and acceleration programmes will be introduced by Roger Salvat. Diego Velasco Escribano will present the Red iTemas network which is identifying high potential impact projects and supporting technology transfer efforts to the national health system and the industry. Thomas Tan, Principal at Sound Bioventures, will share his experience as strategic consultant, entrepreneur and venture capitalist at Lundbeck Fonden Ventures and Sound Bioventures. Miranda Knaggs, a director at The Pioneer Group, will share her organization’s experience with startup incubators and investment, scale up and accelerator programmes.

Sponsored by:

• Ángel Sánchez, Partner, SILO

• Roger Salvat, Business Development Manager, CaixaBank DayOne
• Diego Velasco, Head of Innovation, Ramón y Cajal Health Research Institute (iTemas Network)
• Thomas Tan, Principal, Sound Bioventures
• Miranda Knaggs, Corporate Development Director, Pioneering Ventures (Pioneer Group)

• Ion Arocena, CEO, AseBio – Spanish Bioindustry Association